Articles tagged with Drug Development
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Researchers achieved a new method for synthesizing α-substituted carbonyl compounds using a palladium-catalyzed anti-Michael addition reaction. The method produces high-yield products and can be applied to various nucleophiles, including indoles and aromatic compounds.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Researchers have successfully developed mercury selenide and cadmium selenide nanocrystals that absorb and emit in the infrared spectrum, retaining desired properties of their parent CdSe nanocrystals. This breakthrough technology has potential to revolutionize molecular probing for imaging in biological systems.
A Phase 2 clinical trial demonstrated the effectiveness of OXO-001 in increasing embryo implantation, pregnancy and live birth rates among infertile women. The study showed significant improvements in biochemical, clinical and ongoing pregnancy rates, with a notable increase in live birth rates.
Researchers at MIT have developed a new way to make microbes hardy enough to withstand industrial processing, high temperatures, radiation, and long-term storage. The method involves mixing bacteria with food and drug additives, resulting in stable formulations that can be used in various applications.
Scientists have mapped over 5,000 genetic variants in the 'tumour protection' gene BAP1 that significantly increase cancer risk. These variants can be used to develop new treatments, including IGF-1 inhibitors, to slow down or prevent cancer progression.
A new machine learning-based method uses 3D structure of protein backbone with large language models to predict molecular changes that lead to better antibody drugs. The approach resulted in a 25-fold improvement against a virus, outperforming traditional methods that rely on generating huge amounts of data about protein sequences.
Researchers develop new method to create azetidines, a stable form of heterocycle that don't oxidize under physiological conditions, expanding toolkit for drug developers to improve medication safety and reduce side effects. This breakthrough enables the creation of more useful chemical transformations with better medical functions.
Researchers discovered Pradimicin A's molecular basis for binding to viral N-glycan, showing promise as an anti-SARS-CoV-2 drug. The compound inhibits SARS-CoV-2 infectivity by interacting with branched oligomannose-containing glycans.
Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.
A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.
Researchers at UCSF have discovered a way to turn ordinary white fat cells into beige fat cells that burn calories, opening the door to developing new weight-loss drugs. The approach uses a protein called KLF-15 and may avoid side effects associated with current treatments.
A new mouse study suggests that elenolic acid can lower blood sugar levels and promote weight loss in obese mice with diabetes. The compound was found to induce the release of metabolic hormones GLP-1 and PYY, leading to improved glucose regulation and insulin sensitivity.
Researchers at Moffitt Cancer Center have developed a groundbreaking synthesis method for producing withanolides, a class of compounds that inhibit cancer cell growth and induce cell death. The scalable production of these compounds will advance cancer research and treatment development, offering new hope for patients.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
A Phase 1 clinical trial is underway to evaluate the safety and efficacy of an investigational monoclonal antibody targeting enterovirus D68 (EV-D68), a virus associated with severe respiratory and neurological diseases. The trial will assess the antibody's potency, duration of action, and optimal dose in healthy volunteers.
Double-membrane vesicles form five common shapes through spontaneous self-organization, offering insight into lipid body intricacies. The study's findings could inspire synthetic materials and bio-inspired drug delivery systems.
Lenacapavir has shown 100% efficacy as PrEP among cisgender women in a Phase 3 clinical trial. The twice-yearly injection offers improved feasibility of PrEP for those experiencing barriers to daily pill-taking. NIAID looks forward to additional data and regulatory decisions.
A new global definition of sarcopenia is proposed, aiming to unify research and clinical practice. The definition may help identify low muscle mass or strength in older people, increasing the risk of poor outcomes such as fragility and disability.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers have developed three new cellular models of myotonic dystrophy type 1 that accurately represent the clinical diversity of the disease. The models show great heterogeneity in genetic expansion and molecular alterations, making them suitable for studying pathophysiology and testing therapeutic options.
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.
Researchers have developed a method to deliver drugs to specific areas of the body using ultrasound waves, triggering drug release from stable nanocarriers. The approach is made both safe and efficient for the first time, paving the way for clinical trials.
Researchers found that carrying just one copy of the Christchurch variant delayed cognitive decline and dementia in family members, with some showing lower levels of tau proteins. The study suggests potential benefits for drug development targeting this genetic pathway.
Researchers developed two clinical ageing clocks, PCAge and LinAge, that use blood tests, a urine test, and a health questionnaire to estimate future mortality risk. These clocks show significant predictive efficacy in characterising individual future ageing trajectories.
A Kobe University study finds that a new treatment for neuromyelitis optica spectrum disorder shifts the balance of immune cells, increasing anti-inflammatory signals. The discovery may enable clinicians to determine treatment effectiveness and move towards personalized medicine for autoimmune diseases.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
A new review paper explores the mechanistic links between peripheral vascular dysfunction, cerebral vascular dysfunction, and reduced brain health with aging. The study suggests that targeting fundamental aging mechanisms may be a promising strategy to reduce dementia risk.
The study highlights the potential of omics research and AI tools to disentangle the molecular drivers of Alzheimer’s disease. Key findings include the identification of novel biomarkers for early detection and therapeutic targets, as well as the exploration of genetic factors contributing to AD risk and progression.
The researchers developed a novel viral reporter system called HIV-Tocky, which allows for real-time visualization of HIV dynamics post-viral infection. This innovation provides crucial insights into HIV-1 latency mechanisms and establishes a foundation for developing eradication strategies.
Researchers at Northwestern University discovered an attenuated virus that can help eliminate cancer in mice and prevent future tumor development. The therapy works by raising 'red flags' on tumors to alert immune cells to attack them.
A University of Houston researcher has made a breakthrough discovery about the development of the heart in the womb, revealing that a certain gene deletion can cause a common type of heart muscle disease called left ventricular non-compaction.
The study reveals that the binding sites of USP28 and USP25 inhibitors are identical, leading to non-specific effects. Researchers now aim to develop precise inhibitors targeting either enzyme site to reduce side effects.
Researchers at the University of British Columbia have developed oral insulin drops that can be easily absorbed by the body, potentially replacing insulin injections. The drops contain a unique cell-penetrating peptide that helps insulin navigate through cells and reach the bloodstream quickly.
A study from Michigan Medicine reveals a connection between neutrophil activation and severe cytokine release syndrome (CRS), a potentially life-threatening reaction to CAR T-Cell therapy. Researchers identified biomarkers of NETosis, a process in which neutrophils create webs that may contribute to CRS.
Researchers at the University of North Carolina's Gillings School of Global Public Health have developed a new oral antiviral drug, obeldesivir (GS-5245), which has shown efficacy in treating COVID-19 in mice. The study suggests that obeldesivir could be a promising tool in future pandemic preparedness.
Researchers review Silibinin's efficacy in managing inflammation, a key factor in tumour development and aging. The molecule may reduce drug-related toxicity and increase therapeutic potential in integrated cancer therapies.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers tested seven antibiotics in combination with various natural compounds, finding synergistic effects against multidrug-resistant bacteria. The study suggests combining antibiotics with plant extracts or phytochemicals could be a promising strategy to combat antimicrobial resistance.
Weo electrolyzed water (WEW) has been shown to attenuate cellular senescence in both normal fibroblasts and breast cancer cells. The study found that WEW modulated markers of cellular senescence, inflammation, and stress response genes in a cell type-dependent manner.
Researchers have developed an AI algorithm that can track protein clumping under the microscope in real-time, revolutionizing the study of neurodegenerative disorders. The tool helps identify key characteristics of clumped proteins, which can lead to new therapies.
Researchers developed adhesive hydrogel coatings that eliminate fibrosis, a common issue with medical implants. The coatings bind devices to tissue and prevent the immune system from attacking them.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers at Ochsner Health have developed SRP-001, a novel medication that leverages unique biological mechanisms to alleviate pain without typical side effects. The first-in-human Phase 1 trial confirms SRP-001's safety and tolerability, paving the way for its progression to further clinical stages.
Researchers discovered a link between disrupted developmental dopamine signaling and autism spectrum disorder, highlighting the importance of studying neural development pathways. The study found that dopaminergic signaling disruptions led to neural circuit abnormalities and behavioral phenotypes reminiscent of autism in zebrafish larvae.
A KAUST team developed a simple approach to tackle CRISPR's deletion issue by targeting error-prone DNA repair pathways. By modulating specific genes, they reduced large deletions while enhancing homology-directed repair efficiency.
Researchers Polina A. Loseva and Vadim N. Gladyshev challenge the existing definition of human life, suggesting a new meaning for the 14-day stage in organismal life grounded in recent mechanistic advances and insights from aging studies. This stage defines the separation of soma from the germline and marks the boundary between rejuven...
Researchers have developed a new technique called molecular pixelation, which allows for the analysis of hundreds of proteins simultaneously in individual cells. This provides a more detailed picture of protein distribution and interactions, crucial for understanding cellular function and signaling.
Researchers at the University of Toronto have found a family of natural compounds that stall the unique metabolic process used by parasites to survive in the human gut. The discovery offers potential as new and more effective treatments for parasitic worm infections, which cause debilitating symptoms and developmental defects.
Scientists have found an effective treatment for spitting cobra snakebites by blocking one of the major dermonecrosis-causing toxins with varespladib. The study suggests that this repurposed drug can prevent tissue damage and may become a valuable treatment against black-necked and red spitting cobra venoms.
Researchers at Sylvester Comprehensive Cancer Center have developed a nanoparticle that can penetrate the blood-brain barrier, potentially targeting both primary breast cancer tumors and brain metastases in one treatment. The method shows early promise in preclinical models, where it shrinks breast and brain tumors.
A Purdue University researcher has received a $2.4 million NIH grant to develop novel inhalation therapeutics for resistant lung infections, which have established resistance to antimicrobial drugs and affect over 2.8 million individuals annually in the US, resulting in more than 35,000 deaths.
Researchers have developed a new anticoagulant with an on-off switch, providing rapid control of bleeding risks in surgery and blood clots. The supramolecular approach combines a tsetse fly protein with a synthetic peptide, allowing for the anticoagulant to be rapidly deactivated by introducing correctly matched strands of free PNA.
Scientists have identified a shared gene module in people with depression and cardiovascular disease, providing new markers for both conditions. The study found that genes involved in inflammation are associated with both diseases, explaining why they often occur together.